Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Aristolochic acid

Reversible noncompetitive PLA2 inhibitor.
ALX-270-047-M025 25 mg 56.00 USD
Do you need bulk/larger quantities?
Replaces Prod. #: BML-EI175

Phospholipase A2 (PLA2) inhibitor active against the enzymes found in many snake venoms as well as those of human platelets and synovial fluids. Inhibits ionophore-stimulated PLA2 activity in human neutrophils. Has been shown to be nephropathic and carcinogenic.

Product Specification

Alternative Name:8-Methoxy-6-nitrophenanthrol(3,4-d)-1,3-dioxide-5-carboxylic acid, 6-Nitrophenanthrol(3,4-d)-1,3-dioxide-5-carboxylic acid
Formula:C17H11NO7 (Aristolochic acid I) and C16H9NO6 (Aristolochic acid II)
MW:341.3 (Aristolochic acid I) and 311.3 (Aristolochic acid II)
Source:Isolated from Aristolochia.
CAS:313-67-7 (Aristolochic acid I), 475-80-9 (Aristolochic acid II), 67123-64-2 (mixture)
MI:14: 786
Purity:≥97% (~1:1 mixture of aristolochic acids I (A) and II (B))
Appearance:Yellow solid.
Solubility:Soluble in DMSO or 100% ethanol. Sparingly soluble in water.
Long Term Storage:Ambient
ALX-270-047 structure II
Aristolochic acid II
ALX-270-047 structure I
Aristolochic acid I
Please mouse over
ALX-270-047 structure II ALX-270-047 structure I

Product Literature References

Misexpression of FATTY ACID ELONGATION1 in the Arabidopsis epidermis induces cell death and suggests a critical role for phospholipase A2 in this process: J.J. Reina-Pinto, et al.; Plant Cell 21, 1252 (2009), Abstract; Full Text
Effect of aristolochic acid on intracellular calcium concentration and its links with apoptosis in renal tubular cells: Y.H. Hsin, et al.; Apoptosis 11, 2167 (2006), Abstract;
Aristolochic acid and ’Chinese herbs nephropathy’: a review of the evidence to date: J.P. Cosyns; Drug Saf. 26, 33 (2003), Review, Abstract;
Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy: H.H. Schmeiser, et al.; Cancer Res. 56, 2025 (1996), Abstract;
Selective inhibition of group II phospholipase A2 by quercetin: M. Lindahl & C. Tagesson; Inflammation 17, 573 (1993), Abstract;
Evidence for different mechanisms involved in the formation of lyso platelet-activating factor and the calcium-dependent release of arachidonic acid from human neutrophils: J.D. Winkler, et al.; Biochem. Pharmacol. 44, 2055 (1992), Abstract;
The effects of the phospholipase A2 inhibitors aristolochic acid and PGBx on A23187-stimulated mobilization of arachidonate in human neutrophils are overcome by diacylglycerol or phorbol ester: M.D. Rosenthal, et al.; Biochim. Biophys. Acta 1126, 319 (1992), Abstract;
Suramin alters phosphoinositide synthesis and inhibits growth factor receptor binding in HT-29 cells: R. Kopp & A. Pfeiffer; Cancer Res. 50, 6490 (1990), Abstract;
Effects of aristolochic acid on phospholipase A2 activity and arachidonate metabolism of human neutrophils: M.D. Rosenthal, et al.; Biochim. Biophys. Acta 1001, 3 (1989), Abstract;
Edema-inducing activity of phospholipase A2 purified from human synovial fluid and inhibition by aristolochic acid: B.S. Vishwanath, et al.; Inflammation 12, 549 (1988), Abstract;
Characterization of three edema-inducing phospholipase A2 enzymes from habu (Trimeresurus flavoviridis) venom and their interaction with the alkaloid aristolochic acid: B.S. Vishwanath, et al.; Toxicon 25, 501 (1987), Abstract;
Interaction of aristolochic acid with Vipera russelli phospholipase A2: its effect on enzymatic and pathological activities: B.S. Vishwanath & T.V. Gowda; Toxicon 25, 929 (1987), Abstract;
Interaction of phospholipase A2 from Vipera russelli venom with aristolochic acid: a circular dichroism study: B.S. Vishwanath, et al.; Toxicon 25, 939 (1987), Abstract;

Related Literature

Technical Posters
Arachidonic Acid Metabolites
Arachidonic Acid Metabolites
Download as PDF

All new literature pieces

Recommend this page

For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2019 Enzo Life Sciences, Inc.,